Fujifilm Completes $800-Million Acquisition of Two Cell-Culture Media Companies
Fujifilm has completed its $800-million acquisition of two cell-culture media companies, Santa Ana, California-based Irvine Scientific Sales Company (ISUS) and Tokyo-based IS Japan (ISJ). Fujifilm agreed to acquire the two companies in April 2018.
ISUS and ISJ provide cell-culture media for biopharmaceutical production, in vitro fertilization, and cell therapies. ISUS distributes mainly in the US and Europe, and ISJ distributes mainly in Japan and Asia.
The completed acquisitions are part of a larger strategy by Fujifilm to increase its position in biomanufacturing and related technologies, including for cell therapies. The company says that the acquisition of ISUS and ISJ, along with its advanced chemical synthesis and design capabilities from its photographic film business and the cell preparation and culturing technologies of its group companies, such as Japan Tissue Engineering Co, Cellular Dynamics International, and Fujifilm Diosynth Biotechnologies (its contract development and manufacturing business for biopharmaceuticals), will enable growth of its cell-culture media business.
Fujifilm said the acquisitions will also provide further synergies for its contract development and manufacturing business for biopharmaceuticals, research and development in regenerative medicine, and further expansion of its reagents business.